New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 6, 2014
11:36 EDTMYL, IGTStocks with call strike movement; IGT MYL
International Game (IGT) July 18 call option implied volatility increased 8% to 37, Mylan (MYL) July 65 call option implied volatility increased 2% to 36 according to IVolatility.
News For IGT;MYL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 20, 2015
14:37 EDTMYLTeva generic competition to Copaxone pushed out by ruling, says BMO Capital
Subscribe for More Information
12:56 EDTMYLMylan says continues to believe '808 patent is 'invalid'
Subscribe for More Information
10:40 EDTMYLMomenta Pharma sinks after Supreme Court rules on Copaxone
Subscribe for More Information
January 16, 2015
10:27 EDTIGTOptions with increasing implied volatility
Subscribe for More Information
January 15, 2015
14:31 EDTMYLMylan launches generic Epivir-HBV tablets
Mylan (MYL) announced the U.S. launch of its Lamivudine Tablets, 100 mg, which is the generic version of GlaxoSmithKline's (GSK) Epivir-HBV. Mylan received final approval from the U.S. FDA for its Abbreviated New Drug Application for this product, which is indicated for the treatment of chronic hepatitis B virus infection associated with evidence of hepatitis B viral replication and active liver inflammation. Lamivudine Tablets, 100 mg, had U.S. sales of approximately $18.1M for the 12 months ending September 30, 2014, according to IMS Health. Currently, Mylan has 284 ANDAs pending FDA approval representing $109.1B in annual brand sales, according to IMS Health. Forty-four of these pending ANDAs are potential first-to-file opportunities, representing $29.3B in annual brand sales, for the 12 months ending June 30, 2014, according to IMS Health.
January 12, 2015
07:17 EDTMYLJPMorgan to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use